Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut - the effect of diltiazem on the time-course of exposure to triazolam.

[1]  Sara K Quinney,et al.  Semiphysiologically Based Pharmacokinetic Models for the Inhibition of Midazolam Clearance by Diltiazem and Its Major Metabolite , 2009, Drug Metabolism and Disposition.

[2]  Kairui Feng,et al.  The Simcyp® Population-based ADME Simulator , 2009 .

[3]  Z. Barter,et al.  Covariation of Human Microsomal Protein Per Gram of Liver with Age: Absence of Influence of Operator and Sample Storage May Justify Interlaboratory Data Pooling , 2008, Drug Metabolism and Disposition.

[4]  Masoud Jamei,et al.  Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. , 2008, Current drug metabolism.

[5]  Masoud Jamei,et al.  Prediction of intestinal first-pass drug metabolism. , 2007, Current drug metabolism.

[6]  Caroline A. Lee,et al.  Sequential Metabolism Is Responsible for Diltiazem-Induced Time-Dependent Loss of CYP3A , 2007, Drug Metabolism and Disposition.

[7]  Malcolm Rowland,et al.  Mechanistic Approaches to Volume of Distribution Predictions: Understanding the Processes , 2007, Pharmaceutical Research.

[8]  Karthik Venkatakrishnan,et al.  Mechanism-Based Inactivation of Human Cytochrome P450 Enzymes and the Prediction of Drug-Drug Interactions , 2007, Drug Metabolism and Disposition.

[9]  Amir Heydari,et al.  Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA , 2006, Journal of psychopharmacology.

[10]  G. Tucker,et al.  Prediction of in vivo drug clearance from in vitro data. I: Impact of inter-individual variability , 2006, Xenobiotica; the fate of foreign compounds in biological systems.

[11]  Amin Rostami-Hodjegan,et al.  Changes in liver volume from birth to adulthood: A meta‐analysis , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[12]  Kiyomi Ito,et al.  CYP3A4 Substrate Selection and Substitution in the Prediction of Potential Drug-Drug Interactions , 2005, Journal of Pharmacology and Experimental Therapeutics.

[13]  Caroline A. Lee,et al.  EVALUATION OF TIME-DEPENDENT INACTIVATION OF CYP3A IN CRYOPRESERVED HUMAN HEPATOCYTES , 2005, Drug Metabolism and Disposition.

[14]  Aleksandra Galetin,et al.  UTILITY OF RECOMBINANT ENZYME KINETICS IN PREDICTION OF HUMAN CLEARANCE: IMPACT OF VARIABILITY, CYP3A5, AND CYP2C19 ON CYP3A4 PROBE SUBSTRATES , 2004, Drug Metabolism and Disposition.

[15]  Amin Rostami-Hodjegan,et al.  Cytochrome P450 3A expression and activity in the human small intestine , 2004, Clinical pharmacology and therapeutics.

[16]  Yvonne S. Lin,et al.  Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[17]  Oliver Burk,et al.  Cytochrome P450 3A4 and P‐glycoprotein Expression in Human Small Intestinal Enterocytes and Hepatocytes: A Comparative Analysis in Paired Tissue Specimens , 2004, Clinical pharmacology and therapeutics.

[18]  Amin Rostami-Hodjegan,et al.  The effects of dose staggering on metabolic drug-drug interactions. , 2003, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[19]  D. Greenblatt,et al.  Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice , 2003, Clinical pharmacology and therapeutics.

[20]  Kiyomi Ito,et al.  Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[21]  Scott L Cockroft,et al.  The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[22]  E. Molden,et al.  Pharmacokinetics of diltiazem and its metabolites in relation to CYP2D6 genotype , 2002, Clinical pharmacology and therapeutics.

[23]  K. Yeo,et al.  Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes. , 2001, British journal of clinical pharmacology.

[24]  S D Hall,et al.  An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[25]  P. Neuvonen,et al.  Effect of grapefruit juice dose on grapefruit juice–triazolam interaction: repeated consumption prolongs triazolam half-life , 2000, European Journal of Clinical Pharmacology.

[26]  S. Hall,et al.  The interaction of diltiazem with simvastatin , 2000, Clinical pharmacology and therapeutics.

[27]  R. Obach,et al.  Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[28]  D. Jones,et al.  Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation. , 1999, The Journal of pharmacology and experimental therapeutics.

[29]  G. Tucker,et al.  Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes. , 1999, British journal of clinical pharmacology.

[30]  D. Greenblatt,et al.  Inhibition of triazolam clearance by macrolide antimicrobial agents: In vitro correlates and dynamic consequences , 1998, Clinical pharmacology and therapeutics.

[31]  Y. Sugiyama,et al.  Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. , 1998, Pharmacological reviews.

[32]  E. Steiner,et al.  Time course of enzyme induction in humans: Effect of pentobarbital on nortriptyline metabolism , 1998, Clinical pharmacology and therapeutics.

[33]  D. Shen,et al.  Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. , 1997, The Journal of pharmacology and experimental therapeutics.

[34]  M. Murray,et al.  Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites. , 1997, The Journal of pharmacology and experimental therapeutics.

[35]  J. Leonard,et al.  Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects , 1997, Antimicrobial agents and chemotherapy.

[36]  P. Maurel The use of adult human hepatocytes in primary culture and other in vitro systems to investigate drug metabolism in man , 1996 .

[37]  M. Fromm,et al.  Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin , 1996, Hepatology.

[38]  R. Davies,et al.  Pharmacokinetic and pharmacodynamic interactions between diltiazem and quinidine , 1996, Clinical pharmacology and therapeutics.

[39]  P. Neuvonen,et al.  Diltiazem enhances the effects of triazolam by inhibiting its metabolism , 1996, Clinical pharmacology and therapeutics.

[40]  D E Salazar,et al.  Coadministration of nefazodone and benzodiazepines: III. A pharmacokinetic interaction study with alprazolam. , 1995, Journal of clinical psychopharmacology.

[41]  P. Kroboth,et al.  Triazolam pharmacokinetics after intravenous, oral, and sublingual administration. , 1995, Journal of clinical psychopharmacology.

[42]  R B Smith,et al.  Pharmacokinetics and pharmacodynamics of triazolam after two intermittent doses in obese and normal-weight men. , 1995, Journal of clinical psychopharmacology.

[43]  P. Neuvonen,et al.  Dose of midazolam should be reduced during diltiazem and verapamil treatments. , 1994, British journal of clinical pharmacology.

[44]  M. Quilliam,et al.  Pharmacokinetics and metabolism of diltiazem in healthy males and females following a single oral dose , 1993, European Journal of Drug Metabolism and Pharmacokinetics.

[45]  C. Bonfils,et al.  Identification of the rabbit and human cytochromes P-450IIIA as the major enzymes involved in the N-demethylation of diltiazem. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[46]  K. Giacomini,et al.  The pharmacokinetics and pharmacodynamics of diltiazem and its metabolites in healthy adults after a single oral dose , 1989, Clinical pharmacology and therapeutics.

[47]  L. Nilsson,et al.  Pharmacokinetics of diltiazem and its metabolites after single and multiple dosing in healthy volunteers. , 1989, Therapeutic drug monitoring.

[48]  A. Fraser Urinary screening for alprazolam, triazolam, and their metabolites with the EMIT d.a.u. benzodiazepine metabolite assay. , 1987, Journal of analytical toxicology.

[49]  D. Abernethy,et al.  N-monodesmethyldiltiazem is the predominant metabolite of diltiazem in the plasma of young and elderly hypertensives. , 1987, British journal of clinical pharmacology.

[50]  D. Greenblatt,et al.  Population study of triazolam pharmacokinetics. , 1986, British journal of clinical pharmacology.

[51]  P. Kroboth,et al.  Effect of oral contraceptives on triazolam, temazepam, alprazolam, and lorazepam kinetics , 1984, Clinical pharmacology and therapeutics.

[52]  H. Ochs,et al.  Pharmacokinetics and absolute bioavailability of diltiazem in humans , 1984, Klinische Wochenschrift.

[53]  D. Greenblatt,et al.  Concentration‐independent plasma protein binding of benzodiazepines , 1983, The Journal of pharmacy and pharmacology.

[54]  D. Greenblatt,et al.  Reduced clearance of triazolam in old age: relation to antipyrine oxidizing capacity. , 1983, British journal of clinical pharmacology.

[55]  R. Cutler,et al.  Time‐course of interaction between carbamazepine and clonazepam in normal man , 1978, Clinical pharmacology and therapeutics.

[56]  D. London,et al.  Pharmacokinetics of diltiazem after intravenous and oral administration , 2004, European Journal of Clinical Pharmacology.

[57]  C. Regårdh,et al.  Relationship between time of intake of grapefruit juice and its effect on pharmacokinetics and pharmacodynamics of felodipine in healthy subjects , 2004, European Journal of Clinical Pharmacology.

[58]  A. Åsberg,et al.  Desacetyl-diltiazem displays severalfold higher affinity to CYP2D6 compared with CYP3A4. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[59]  Y. Sawada,et al.  Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model. , 2000, British journal of clinical pharmacology.

[60]  J. Smith,et al.  Comparison of rubidium-86 and potassium-42 fluxes in rat aorta. , 1986, Blood vessels.

[61]  Kölle Eu,et al.  Pharmacokinetic model of diltiazem. , 1983 .